13526-66-4

Usage

Uses

Used in Pharmaceutical Industry:
3-Bromo-6-chloroimidazo[1,2-b]pyridazine is used as a reagent for the synthesis of imidazopyridazine series of inhibitors. These inhibitors are specifically designed to target Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1), which plays a crucial role in the survival and growth of the Plasmodium parasite responsible for malaria. By inhibiting PfCDPK1, these compounds can potentially help in the development of novel antimalarial drugs, offering a new approach to combat this life-threatening disease.

InChI:InChI=1/C6H3BrClN3/c7-4-3-9-6-2-1-5(8)10-11(4)6/h1-3H

Upstream product

• 6775-78-6 6-chloroimidazo[1,2-b]pyridazine 

Downstream Products

• 1022981-76-5 (3-bromo-imidazo[1,2-b]pyridazin-6-yl)-(3-fluoro-benzyl)-amine 
• 1022981-72-1 trans-4-(3-bromoimidazo[1,2-b]pyridazin-6-ylamino)cyclohexanol 
• 1022981-74-3 (3-bromo-imidazo[1,2-b]pyridazin-6-yl)-(2,5-difluoro-benzyl)-amine 
• 928337-00-2 6-chloro-3-(3-(trifluoromethoxy)phenyl)imidazo[1,2-b]pyridazine 
• 1025065-58-0 C₂₀H₁₁F₆N₃O₂ 
• 1025065-53-5 C₁₄H₁₃ClN₄ 
• 1025065-93-3 [4-(6-chloro-imidazo[1,2-b]pyridazin-3-yl)-phenyl]-dimethylamine 
• 1084952-98-6 6-chloro-3-(3,4-dimethoxyphenyl)imidazo[1,2-b]pyridazine 
• 1084952-97-5 3-bromo-6-(3,4-dimethoxyphenyl)imidazo[1,2-b]pyridazine 
• 1084951-16-5 3,6-bis(3,4-dimethoxyphenyl)imidazo[1,2-b]pyridazine 
• 1082604-63-4 4-(6-chloroimidazo[1,2-b]pyridazin-3-yl)benzonitrile 
• 1196551-98-0 3-bromo-6-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazine 
• 1196551-90-2 4-(3-bromoimidazo[1,2-b]pyridazin-6-yl)-3-(3-fluorophenyl)morpholine 
• 1196551-94-6 (3S)-1-(3-bromoimidazo[1,2-b]pyridazin-6-yl)-2-(3-fluorophenyl)pyrrolidin-3-ol 

Relevant academic research and scientific papers

Synthesis and antifungal activity of imidazo[1,2-b]pyridazine derivatives against phytopathogenic fungi

A series of 3,6-disubstituted imidazo[1,2-b]pyridazine derivatives have been synthesized and characterized with spectroscopic analyses. The antifungal activities of these compounds against nine phytopathogenic fungi were evaluated by the mycelium growth rate method. The in vitro antifungal bioassays indicated that most of compounds displayed excellent and broad-spectrum antifungal activities. Especially, compounds 4a, 4c, 4d, 4l and 4r exhibited 1.9–25.5 fold more potent than the commercially available fungicide hymexazol against Corn Curvalaria Leaf Spot (CL), Alternaria alternate (AA), Pyricularia oryzae (PO) and Alternaria brassicae (AB) strains. Structure-activity relationship analysis showed that the enhanced antifungal activity is significantly affected by the substituents on the benzene ring and pyridazine ring.

Application of 3,6-disubstituted imidazo[1, 2-b] pyridazine derivatives in preparation of fungicides

The invention belongs to the technical field of farm chemicals, and specifically relates to application of 3,6-disubstituted imidazo[1, 2-b] pyridazine derivatives in preparation of fungicides. The 3,6-disubstituted imidazo[1, 2-b] pyridazine derivatives are prepared and applied in farm chemical preparation. The inhibition activity of the derivatives on nine common plant pathogenic fungi is testedby adopting a hypha growth rate inhibition method; some of the derivatives show excellent fungistat activity, and are expected to be used for preventing and treating plant diseases caused by pathogenic fungi such as wheat scab, rice blast, cotton blight, tobacco brown spot, cabbage black spot, pumpkin blight, apple ring spot, Curvularia lunata(Walk) Boed and potato dry rot.

Exploration of the imidazo[1,2-b]pyridazine scaffold as a protein kinase inhibitor

3,6-Disubstituted imidazo[1,2-b]pyridazine derivatives were synthesized to identify new inhibitors of various eukaryotic kinases, including mammalian and protozoan kinases. Among the imidazo[1,2-b]pyridazines tested as kinase inhibitors, several derivatives were selective for DYRKs and CLKs, with IC50?50?=?82?nM), CLK4 (IC50?=?44?nM), DYRK1A (IC50?=?50?nM), and PfCLK1 (IC50?=?32?nM). The compounds were also tested against Leishmania amazonensis. Several compounds showed anti-leishmanial activity at rather high (10?μM) concentration, but were not toxic at 1?μM or 10?μM, as judged by viability assays carried out using a neuroblastoma cell line.

AMIDO-SUBSTITUTED IMIDAZOPYRIDAZINES USEFUL IN THE TREATMENT OF HYPER-PROLIFERATIVE AND/OR ANGIOGENESIS DISORDERS

The present invention relates to amido-substituted imidazopyridazine compounds of general formula (I): in which A, E, R2, R3, R4 and n are as defined in the claims, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.

6-HYDROXYBENZOFURANYL- AND 6-ALKOXYBENZOFURANYL-SUBSTITUTED IMIDAZOPYRIDAZINES

The present invention relates to 6-hydroxybenzofuranyl- and 6-alkoxybenzofuranyl- substituted imidazopyridazine compounds of general formula (I) in which R1 and R2 are as defined in the claims, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.

AMINO-SUBSTITUTED IMIDAZOPYRIDAZINES

The present invention relates to amino-substituted imidazopyridazine compounds of general formula (I), in which A, R1, R2, R3, R4, R5 and n are as defined in the claims, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.

AMIDO-SUBSTITUTED IMIDAZOPYRIDAZINES USEFUL IN THE TREATMENT OF HYPER-PROLIFERATIVE AND/OR ANGIOGENESIS DISORDERS

The present invention relates to amido-substituted imidazopyridazine compounds of general formula (I): in which A, E, R2, R3, R4 and n are as defined in the claims, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper- proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.

(R)-2-Phenylpyrrolidine substituted imidazopyridazines: A new class of potent and selective pan-TRK inhibitors

Deregulated kinase activities of tropomyosin receptor kinase (TRK) family members have been shown to be associated with tumorigenesis and poor prognosis in a variety of cancer types. In particular, several chromosomal rearrangements involving TRKA have be

ARYL AMIDE KINASE INHIBITORS

The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.

SUBSTITUTED-IMIDAZO[1,2-B]PYRIDAZINES AS MKNK1 INHIBITORS

The present invention relates to amido-substituted imidazopyridazine compounds of general formula (I): (Ia) (Ib) (Ic) (Id) in which A, Y, R1, R2, R3, R4 and n are as defined in the claims, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.